Amgen announces $5 billion stock repurchase plan

By Jennifer Chiou

New York, Dec. 7 - Amgen Inc. said its board of directors authorized additional repurchases of up to $5 billion of stock.

The company has $2 billion remaining under its previous stock repurchase program.

Thousand Oaks, Calif.-based Amgen is a biotechnology company that develops therapeutics for cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.